Article Access statistics

Viewed: 877

Emailed: 0

PDF Downloaded: 308

Indian Journal of Pharmacy and Pharmacology

Study of prescribing pattern in patients with gastro-oesophageal carcinoma in a tertiary care hospital

Full Text PDF Share on Facebook Share on Twitter

Author Details : VT Annapurna, HV Anuradha, MC Shivamurthy

Volume : 4, Issue : 2, Year : 2017

Article Page : 69-71

Suggest article by email


Introduction: Esophageal carcinoma (EC) ranks 6th among all cancers in mortality. Gastric carcinoma (GC) is the 2nd most common cancer among men and 3rd most among females in Asia and worldwide. The aetiology in majority of patients was linked to tobacco and alcohol. Usually, treatment regimen followed EC, GEJ (gastroesophageal junction) and gastric carcinoma is DCF regimen as per National Comprehensive Cancer Network guidelines.
Objectives: To study the prescribing pattern in esophageal cancer, GEJ cancer & gastric carcinoma in a tertiary care hospital.
Materials and Method: A prospective observational study was done for a period of 6 months in both male & female patients diagnosed with EC, GEJ & GC. Prescribing patterns were recorded & analysed.
Results and Discussion: Total of 31 patients was included in the study; of which 19, 9 & 3 were diagnosed as EC, GC and GEJ carcinoma respectively. The most common treatment regimen followed were combination of cisplatin+5 fluorouracil+ radiotherapy in EC & GEJ whereas oxaliplatin +5-fluorouracil + leucovorin in GC.
Conclusion: In our study, anticancer drugs were prescribed in a combination therapy. In majority of upper gastrointestinal carcinoma patients 5-FU and platinum based combination therapy were used. Dexamethasone, granisetron and ondensetron were used to treat adverse drug reactions of anticancer drugs.

Esophageal carcinoma; Gastric Carcinoma; GEJ carcinoma

How to cite : Annapurna V, Anuradha H, Shivamurthy M, Study of prescribing pattern in patients with gastro-oesophageal carcinoma in a tertiary care hospital. Indian J Pharm Pharmacol 2017;4(2):69-71

Copyright © 2017 by author(s) and Indian J Pharm Pharmacol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (